Clinical Trials Logo

Irritable Bowel Disease clinical trials

View clinical trials related to Irritable Bowel Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05640583 Completed - Clinical trials for Irritable Bowel Disease

Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers

Start date: March 16, 2022
Phase: N/A
Study type: Interventional

To assess the differential expression of IBD-related microbiome-derived biomarkers including bacterial strains and peptides such as antimicrobial peptides (AMP) found in inner-colonic samples (HygiSample™) in comparison to home collected stool samples in patients with active IBD colonic disease. The HygiSample will be collected during a defecation-inducing high-volume (>40 L) colon irrigation bowel prep (HygiPrepⓇ).

NCT ID: NCT04879810 Completed - Clinical trials for Irritable Bowel Disease

Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The trial will test the hypothesis that edible structures within plant cells (ginger) will have clinically important anti-inflammatory effects on the gut lining of patients with inflammable bowel disease. To evaluate the safety and tolerability of exosomes with and without curcumin in patients with Inflammatory Bowel Disease (IBD); To estimate the effect of ginger exosomes or curcumin alone or combined with curcumin on the symptoms and disease score in patients with refractory IBD describe toxicities associated with ginger exosomes; to evaluate the effect of ginger exosomes on biomarkers of inflammation.

NCT ID: NCT03186872 Completed - Anxiety Clinical Trials

Improving Quality of Care With a Digital Behavioral Program in IBD Patient Centered Medical Home

Start date: May 15, 2017
Phase: N/A
Study type: Interventional

Anxiety disorders and depression are more prevalent in patients living with inflammatory bowel disease (IBD) than in healthy controls. Approximately 40% of IBD patients have elevated anxiety. Given the robust effectiveness of cognitive behavioral approaches for anxiety disorders and the paucity or mixed findings of cognitive behavioral approaches for anxiety in IBD, an integrated behavioral approach and combining face to face and online cognitive behavioral modalities is recommended for IBD patients with anxiety.

NCT ID: NCT02372201 Completed - Clinical trials for Irritable Bowel Disease

Effects of Fasting and Hydro Colon Therapy Plus Probiotics on GI Microbiota in Intolerances and Irritable Bowel Syndrome

MicFFGAH2013
Start date: January 2013
Phase: N/A
Study type: Interventional

Consequences of Colon Hydrotherapy plus probiotic intervention on composition of GI microbiota and well being are analysed in subjects claiming GI inconveniences due to Irritable Bowel Syndrome or food intolerances.

NCT ID: NCT02026518 Completed - Clinical trials for Irritable Bowel Disease

Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome

Start date: January 2014
Phase: Phase 4
Study type: Interventional

Fasting blood specimens will be taken from the patients with IBS that have inclusion criteria. First, the objectives and method of study will be explained to the patients and informed consent form will be taken from them. They will be divided into 4 groups by an adjusted randomized blocking and the clinical outcomes, quality of life, emotional stress questionnaires will be completed before and after intervention. During 6 weeks, they will receive 2 capsules of soy isoflavones per day, 50000IU vitamin D biweekly in addition to the other placebo form, both of them and placebo of both. At the end, body mass index ( BMI), serum TNF-Alpha, TAC, gene expression of GATA3, ROR gamma, FOXP3 in lymphocytes and gut permeability will be measured. The quantity of polymorphisms of vitamin D and estrogen receptors will be determined.